[High throughput sequencing for detection of 82 kinds of hematologic malignancy related gene mutations in patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors]

Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):866-869. doi: 10.3760/cma.j.issn.0253-2727.2019.10.015.

[Article in Chinese]

Authors

H F Zhao¹, Yanli Zhang¹, X D Lyu¹, Z Guo¹, J Y Yang², Z Li¹, Y L Zu¹, J Zhou¹, F K Yu¹, Y P Song¹

Affiliations

¹ Department of Hematology, Henan Cancer Hospital, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
² Beijing Institute of Genome, Chinese Academy of Sciences, Beijing 100101, China.

PMID: 31775490
PMCID: PMC7364976
DOI: 10.3760/cma.j.issn.0253-2727.2019.10.015

No abstract available

MeSH terms

Antineoplastic Agents
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl
Hematologic Neoplasms*
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
Mutation
Protein Kinase Inhibitors

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl